Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | PRKDC | P78527 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23053033 | 0.90 | ALDH1A1 (0.43) | ALDH1A1CYP3A4KDM4EMAPTALOX15 | |
| SCHEMBL13935167 | 0.89 | TDP1 (0.41) | ALDH1A1CYP3A4KDM4EMAPTALOX15 | |
| SCHEMBL15926489 | 0.87 | ALOX15 (0.42) | ALDH1A1CYP3A4KDM4EMAPTALOX15 | |
| SCHEMBL12436736 | 0.86 | ALDH1A1 (0.54) | ALDH1A1CYP3A4KDM4EMAPTALOX15 | |
| SCHEMBL20620427 | 0.85 | HTT (0.40) | ALDH1A1CYP3A4KDM4EMAPTALOX15 | |
| SCHEMBL2187742 | 0.84 | ALDH1A1 (0.53) | ALDH1A1CYP3A4KDM4EMAPTALOX15 | |
| Ammonia Solution, Strong SCHEMBL27817247 | 0.84 | ALDH1A1 (0.53) | ALDH1A1CYP3A4KDM4EMAPTALOX15 | |
| SCHEMBL22691535 | 0.83 | ALDH1A1 (0.53) | ALDH1A1CYP3A4KDM4EMAPTALOX15 | |
| SCHEMBL3790682 | 0.83 | LMNA (0.44) | ALDH1A1CYP3A4KDM4EMAPTALOX15 | |
| SCHEMBL18650006 | 0.83 | ALDH1A1 (0.51) | ALDH1A1CYP3A4KDM4EMAPTALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11129790-B2 | Chemo-enzymatic site-specific modification of peptides and proteins to form cleavable conjugates | NORTHEASTERN UNIVERSITY (US) | 2021-09-28 | — | — | US | disclosed |
| US-20180369131-A1 | Chemo-Enzymatic Site-Specific Modification of Peptides and Proteins to Form Cleavable Conjugates | NORTHEASTERN UNIVERSITY | 2018-12-27 | — | — | US | disclosed |
| US-20100029643-A1 | HETEROCYCLYC SULFONAMIDES HAVING EDG-1 ANTAGONISTIC ACTIVITY | ASTRAZENECA AB (SE) | 2010-02-04 | — | — | US | disclosed |
| EP-2094670-A1 | HETEROCYCLYC SULFONAMIDES HAVING EDG-I ANTAGONISTIC ACTIVITY | AstraZeneca AB (SE) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008056150-A1 | HETEROCYCLYC SULFONAMIDES HAVING EDG-I ANTAGONISTIC ACTIVITY | ASTRAZENECA AB (SE) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180369131-A1 | Chemo-Enzymatic Site-Specific Modification of Peptides and Proteins to Form Cleavable Conjugates | GLUL, QPCT, DNPEP | ALDH1A1 3701/4885CYP3A4 1957/4885KDM4E 2129/4885 |
| US-11129790-B2 | Chemo-enzymatic site-specific modification of peptides and proteins to form cleavable conjugates | GLUL, QPCT, DNPEP | ALDH1A1 3701/4885CYP3A4 1957/4885KDM4E 2129/4885 |
| US-20100029643-A1 | HETEROCYCLYC SULFONAMIDES HAVING EDG-1 ANTAGONISTIC ACTIVITY | EDF1, ERLIN1, ECE1 | ALDH1A1 1056/4885CYP3A4 3081/4885KDM4E 2122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.